Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its …
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the first patient has been dosed in its Halo-301 …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported financial results for the fourth quarter and full year ended December 31, 2015, which included a fourth quarter increase …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with …
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided key program updates and its Annual financial guidance …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that it has entered into a $150 million credit agreement, secured by future royalties of ENHANZE™ products, received only …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced a global collaboration and license agreement with Eli Lilly and Co (NYSE:LLY) to develop and commercialize products combining …
Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Eisai Inc.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will be expanding its facilities by opening a …
Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the third quarter endedSeptember 30, 2015.
